We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Hims & Hers Health, Inc. (HIMS) Ascends While Market Falls: Some Facts to Note
Read MoreHide Full Article
Hims & Hers Health, Inc. (HIMS - Free Report) closed at $31.89 in the latest trading session, marking a +1.33% move from the prior day. This change outpaced the S&P 500's 1.22% loss on the day. On the other hand, the Dow registered a loss of 0.98%, and the technology-centric Nasdaq decreased by 1.35%.
Shares of the company witnessed a gain of 40.24% over the previous month, beating the performance of the Medical sector with its gain of 4.11%, and the S&P 500's gain of 1.56%.
Analysts and investors alike will be keeping a close eye on the performance of Hims & Hers Health, Inc. in its upcoming earnings disclosure. The company's earnings per share (EPS) are projected to be -$0.08, reflecting a 147.06% decrease from the same quarter last year. At the same time, our most recent consensus estimate is projecting a revenue of $689.29 million, reflecting a 26.52% rise from the equivalent quarter last year.
For the entire fiscal year, the Zacks Consensus Estimates are projecting earnings of -$0.09 per share and a revenue of $2.91 billion, representing changes of -116.98% and +23.78%, respectively, from the prior year.
Investors should also pay attention to any latest changes in analyst estimates for Hims & Hers Health, Inc. These revisions help to show the ever-changing nature of near-term business trends. Consequently, upward revisions in estimates express analysts' positivity towards the business operations and its ability to generate profits.
Our research reveals that these estimate alterations are directly linked with the stock price performance in the near future. To capitalize on this, we've crafted the Zacks Rank, a unique model that incorporates these estimate changes and offers a practical rating system.
The Zacks Rank system, spanning from #1 (Strong Buy) to #5 (Strong Sell), boasts an impressive track record of outperformance, audited externally, with #1 ranked stocks yielding an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has remained steady. Hims & Hers Health, Inc. is currently a Zacks Rank #5 (Strong Sell).
Valuation is also important, so investors should note that Hims & Hers Health, Inc. has a Forward P/E ratio of 786.75 right now. This indicates a premium in contrast to its industry's Forward P/E of 24.89.
We can also see that HIMS currently has a PEG ratio of 59.04. The PEG ratio bears resemblance to the frequently used P/E ratio, but this parameter also includes the company's expected earnings growth trajectory. Medical Info Systems stocks are, on average, holding a PEG ratio of 1.93 based on yesterday's closing prices.
The Medical Info Systems industry is part of the Medical sector. This group has a Zacks Industry Rank of 157, putting it in the bottom 36% of all 250+ industries.
The Zacks Industry Rank evaluates the power of our distinct industry groups by determining the average Zacks Rank of the individual stocks forming the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Make sure to utilize Zacks.com to follow all of these stock-moving metrics, and more, in the coming trading sessions.
View the Zacks #1 Rank List
Image: Bigstock
Hims & Hers Health, Inc. (HIMS) Ascends While Market Falls: Some Facts to Note
Hims & Hers Health, Inc. (HIMS - Free Report) closed at $31.89 in the latest trading session, marking a +1.33% move from the prior day. This change outpaced the S&P 500's 1.22% loss on the day. On the other hand, the Dow registered a loss of 0.98%, and the technology-centric Nasdaq decreased by 1.35%.
Shares of the company witnessed a gain of 40.24% over the previous month, beating the performance of the Medical sector with its gain of 4.11%, and the S&P 500's gain of 1.56%.
Analysts and investors alike will be keeping a close eye on the performance of Hims & Hers Health, Inc. in its upcoming earnings disclosure. The company's earnings per share (EPS) are projected to be -$0.08, reflecting a 147.06% decrease from the same quarter last year. At the same time, our most recent consensus estimate is projecting a revenue of $689.29 million, reflecting a 26.52% rise from the equivalent quarter last year.
For the entire fiscal year, the Zacks Consensus Estimates are projecting earnings of -$0.09 per share and a revenue of $2.91 billion, representing changes of -116.98% and +23.78%, respectively, from the prior year.
Investors should also pay attention to any latest changes in analyst estimates for Hims & Hers Health, Inc. These revisions help to show the ever-changing nature of near-term business trends. Consequently, upward revisions in estimates express analysts' positivity towards the business operations and its ability to generate profits.
Our research reveals that these estimate alterations are directly linked with the stock price performance in the near future. To capitalize on this, we've crafted the Zacks Rank, a unique model that incorporates these estimate changes and offers a practical rating system.
The Zacks Rank system, spanning from #1 (Strong Buy) to #5 (Strong Sell), boasts an impressive track record of outperformance, audited externally, with #1 ranked stocks yielding an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has remained steady. Hims & Hers Health, Inc. is currently a Zacks Rank #5 (Strong Sell).
Valuation is also important, so investors should note that Hims & Hers Health, Inc. has a Forward P/E ratio of 786.75 right now. This indicates a premium in contrast to its industry's Forward P/E of 24.89.
We can also see that HIMS currently has a PEG ratio of 59.04. The PEG ratio bears resemblance to the frequently used P/E ratio, but this parameter also includes the company's expected earnings growth trajectory. Medical Info Systems stocks are, on average, holding a PEG ratio of 1.93 based on yesterday's closing prices.
The Medical Info Systems industry is part of the Medical sector. This group has a Zacks Industry Rank of 157, putting it in the bottom 36% of all 250+ industries.
The Zacks Industry Rank evaluates the power of our distinct industry groups by determining the average Zacks Rank of the individual stocks forming the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Make sure to utilize Zacks.com to follow all of these stock-moving metrics, and more, in the coming trading sessions.